论文部分内容阅读
目的:分析乙肝肝硬化患者采用阿德福韦酯和拉米夫定联合治疗的临床效果。方法:将我院86例乙肝肝硬化患者按照患者入院就诊顺序随机分为实验组(常规治疗同时采用拉米夫定和阿德福韦酯联合治疗)和对照组(采用常规基础治疗以及拉米夫定治疗),将两组患者白蛋白(ALB)、总胆红素(TBIL)以及谷丙转氨酶(ALT)等肝功能指标治疗前后变化情况、肝脏Child-Pugh评分以及治疗后HBV DNA水平进行对比分析。结果:两组患者AST、ALT以及ABIL等肝功能指标以及Child-Pugh评分治疗前并没有很大差异(P>0.05),实验组患者以上各项指标相对于对照组均显著降低。实验组患者治疗后HBV DNA水平(2.63±0.74)IU/ml明显低于对照组(3.55±0.47)IU/ml,两组差异对比存在统计学意义(P<0.05)。结论:乙肝肝硬化患者采用阿德福韦酯和拉米夫定联合治疗可取得比较满意的临床效果,有利于改善肝功能,增强抗病毒能力,可在临床上推广。
Objective: To analyze the clinical effect of adefovir dipivoxil combined with lamivudine in patients with hepatitis B cirrhosis. Methods: 86 cases of hepatitis B cirrhosis in our hospital were randomly divided into experimental group (conventional treatment combined with lamivudine and adefovir dipivoxil) and control group (conventional basic treatment and lamie The levels of albumin, total bilirubin (TBIL) and alanine aminotransferase (ALT) were measured before and after treatment, the Child-Pugh score of the liver and the level of HBV DNA after treatment Comparative analysis. Results: There was no significant difference between the two groups in the indexes of liver function such as AST, ALT, ABIL and Child-Pugh scores before treatment (P> 0.05). The above indexes in the experimental group were significantly lower than those in the control group. The level of HBV DNA (2.63 ± 0.74) IU / ml in the experimental group was significantly lower than that of the control group (3.55 ± 0.47) IU / ml, the difference between the two groups was statistically significant (P <0.05). Conclusion: The combination of adefovir dipivoxil and lamivudine in patients with hepatitis B cirrhosis can achieve satisfactory clinical results, which is beneficial to improve liver function and enhance anti-virus ability and can be clinically promoted.